Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

OBJECTIVES: Riociguat is approved for pulmonary arterial hypertension and has antiproliferative, anti-inflammatory and antifibrotic effects in animal models of tissue fibrosis. We evaluated the efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcSSc) at hi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Rheum Dis
Glavni autori: Khanna, Dinesh, Allanore, Yannick, Denton, Christopher P, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet E, Atsumi, Tatsuya, Bečvář, Radim, Czirják, László, Hachulla, Eric, Ishii, Tomonori, Ishikawa, Osamu, Johnson, Sindhu R, De Langhe, Ellen, Stagnaro, Chiara, Riccieri, Valeria, Schiopu, Elena, Silver, Richard M, Smith, Vanessa, Steen, Virginia, Stevens, Wendy, Szücs, Gabriella, Truchetet, Marie-Elise, Wosnitza, Melanie, Laapas, Kaisa, de Oliveira Pena, Janethe, Yao, Zhen, Kramer, Frank, Distler, Oliver
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Systemic Sclerosis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213318/
https://ncbi.nlm.nih.gov/pubmed/32299845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216823
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items